Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 1, 2004Expert Opinion on Emerging Drugs

Treatment of Type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors

View Full Paper
Ask AI
Bookmark
Share

Authors

Jens J. Holst
Jens J. HolstStatens Serum Institut

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Jens J. Holst (2004) studied this question.

synapsesocial.com/papers/6a70e5aaa7fbea1e44083feahttps://doi.org/10.1517/14728214.9.1.155
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Glucagon-Like Peptide I Increases Cytoplasmic Calcium in Insulin-Secreting βTC3-Cells by Enhancement of Intracellular Calcium Mobilization1995 · 126 citations
  2. 2Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells.1999 · 321 citations
  3. 3Glucagon-Like Peptide-1 Synthetic Analogs: New Therapeutic Agents for Use in the Treatment of Diabetes Mellitus2003 · 136 citations
  4. 4Long-Term Treatment With Dipeptidyl Peptidase IV Inhibitor Improves Hepatic and Peripheral Insulin Sensitivity in the VDF Zucker Rat2002 · 139 citations
  5. 5GLP‐1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells2003 · 213 citations